Sun Pharmaceutical Industries Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Sun Pharmaceutical Industries Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.9 times. Higher than 91% of Healthcare companies in India.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 7% of its market value (net cash). Higher than 86% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹121Over the last 3 years, every ₹100 of reported profit came with ₹121 of operating cash.
Higher than 56% of Healthcare companies in India.
Self-Funding Ratio
4.9×Over the last 3 years its own operating cash covered its investment spending (capex) 4.9 times.
Higher than 91% of Healthcare companies in India.
Cash Locked Ratio
₹30For every ₹100 of sales, ₹30 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹34 tied up three years earlier.
More money tied up than 63% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹20Sales grew 35% in 3 years; of every extra ₹100 of sales, ₹20 became extra profit.
Higher than 60% of Healthcare companies in India.
Asset Productivity Ratio
+35% / +35%In 3 years sales changed by +35% while total assets changed by +35%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
3.1×Debt due within a year is covered 3.1 times by its yearly operating cash.
Higher than 65% of Healthcare companies in India.
Cash Cushion Ratio
+7%Cash, after subtracting all debt, equals 7% of its market value (net cash).
Higher than 86% of Healthcare companies in India.
Tangible Assets Ratio
79%Of every ₹100 the company owns, ₹79 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 84% of Healthcare companies in India.
Tangible Net Worth Ratio
72%Of every ₹100 of net worth, ₹72 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 78% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Sun Pharmaceutical Industries Limited owes ₹0.23 for every ₹1 it owns. Net profit rose 5% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
34.9Investors pay ₹34.9 for every ₹1 of Sun Pharmaceutical Industries Limited's yearly profit, lower than 54% of Healthcare companies in India.
P/B ratio
5.05The share price is 5.05 times Sun Pharmaceutical Industries Limited's book value per share, higher than 55% of Healthcare companies in India.
Market cap
₹421,803 CrThe total market value of all of Sun Pharmaceutical Industries Limited's shares at today's price (share price × number of shares), larger than almost all Healthcare companies in India. PosiCap size class: Tito Cap.
Net worth (book value)
₹83,570 CrWhat Sun Pharmaceutical Industries Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹348.31Net worth divided by the number of shares. The share price of ₹1,758 is 5.0 times this, which is the P/B above.
Return on equity (ROE)
14.5%Sun Pharmaceutical Industries Limited earned 14.5% on its shareholders' money over the last year, higher than 58% of Healthcare companies in India.
Owes vs Owns
0.23×Sun Pharmaceutical Industries Limited owes ₹0.23 for every ₹1 it owns (low), lower than 79% of Healthcare companies in India.
Dividend yield
0.91%Sun Pharmaceutical Industries Limited pays 0.91% of its share price as dividends a year, higher than 78% of dividend-paying Healthcare companies in India.
Revenue growth
+12%Revenue rose 12% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Profit growth
+5%Net profit rose 5% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Profit margin
19.7%Sun Pharmaceutical Industries Limited keeps ₹20 of every ₹100 of revenue as net profit.
Cash quality
1.08×Cash from Sun Pharmaceutical Industries Limited's business was 1.08× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
40.1×Sun Pharmaceutical Industries Limited's operating profit covered its interest costs 40.1 times in the year to Mar 2026.
Cash vs debt
Net cashSun Pharmaceutical Industries Limited held ₹29,154 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Sun Pharmaceutical Industries Limited's P/E ratio?
Investors pay ₹34.9 for every ₹1 of Sun Pharmaceutical Industries Limited's yearly profit, lower than 54% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Sun Pharmaceutical Industries Limited: ₹421,803 Cr ÷ ₹83,570 Cr (31 Mar 2026) = 5.0.
What is Sun Pharmaceutical Industries Limited's return on equity?
Sun Pharmaceutical Industries Limited earned 14.5% on its shareholders' money over the last year, higher than 58% of Healthcare companies in India.
How much does Sun Pharmaceutical Industries Limited owe compared with what it owns?
Sun Pharmaceutical Industries Limited owes ₹0.23 for every ₹1 it owns (low), lower than 79% of Healthcare companies in India.
Does Sun Pharmaceutical Industries Limited pay a dividend?
Yes. Sun Pharmaceutical Industries Limited pays 0.91% of its share price as dividends a year, higher than 78% of dividend-paying Healthcare companies in India.
Is Sun Pharmaceutical Industries Limited's revenue growing?
Revenue rose 12% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.